PROK logo

PROK
ProKidney Corp

1,833
Mkt Cap
$580.56M
Volume
690,291.00
52W High
$7.13
52W Low
$0.4603
PE Ratio
-3.75
PROK Fundamentals
Price
$1.93
Prev Close
$1.95
Open
$1.98
50D MA
$2.16
Beta
2.50
Avg. Volume
769,920.46
EPS (Annual)
-$0.515
P/B
-0.27
Rev/Employee
$3,865.80
$1,346.04
Loading...
Loading...
News
all
press releases
ProKidney (NASDAQ:PROK) Cut to Sell at Wall Street Zen
Wall Street Zen cut ProKidney from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
Equities Analysts Set Expectations for ProKidney Q1 Earnings
ProKidney Corp. (NASDAQ:PROK - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for ProKidney in a research report issued on Thursday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.12) per share f...
MarketBeat·1d ago
News Placeholder
ProKidney (NASDAQ:PROK) Raised to "Strong-Buy" at Jefferies Financial Group
Jefferies Financial Group upgraded shares of ProKidney to a "strong-buy" rating in a research note on Wednesday...
MarketBeat·2d ago
News Placeholder
ProKidney (NASDAQ:PROK) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
ProKidney (NASDAQ:PROK - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by...
MarketBeat·3d ago
News Placeholder
ProKidney (NASDAQ:PROK) Stock Price Down 4.7% - Time to Sell?
ProKidney (NASDAQ:PROK) Shares Down 4.7% - What's Next...
MarketBeat·5d ago
News Placeholder
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of -175.08% and -13.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
ProKidney (PROK) Projected to Post Earnings on Monday
ProKidney (NASDAQ:PROK) will be releasing its Q4 2025 earnings before the market opens on Monday, March 16. (View Earnings Report at...
MarketBeat·12d ago
News Placeholder
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -100.00% and -2.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
ProKidney (NASDAQ:PROK) Stock Price Up 9% - Here's Why
ProKidney (NASDAQ:PROK) Stock Price Up 9% - What's Next...
MarketBeat·17d ago
News Placeholder
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases DelveInsight
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight Chronic Kidney Disease...
PR Newswire·18d ago
<
1
2
...
>

Latest PROK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.